Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tildacerfont by Spruce Biosciences for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome): Likelihood of Approval
Tildacerfont is under clinical development by Spruce Biosciences and currently in Phase II for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome). According...
Tildacerfont by Spruce Biosciences for Polycystic Ovarian Syndrome: Likelihood of Approval
Tildacerfont is under clinical development by Spruce Biosciences and currently in Phase II for Polycystic Ovarian Syndrome. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Spruce Biosciences's Tildacerfont?
Tildacerfont is a small molecule commercialized by Spruce Biosciences, with a leading Phase II program in Congenital Adrenal Hyperplasia (Adrenogenital...